ROS Therapeutics Holding ApS: Financial statements 2019
CVR: 39507056
Source: annual report 2019, Danish Business Authority
01/01/2019 – 31/12/2019
ROS Therapeutics Holding ApS (CVR 39507056) has filed annual accounts for 2019. In 2019, the company reported a gross profit of DKK -15,000 and a net result of DKK -11,963. Equity in the 2019 report amounted to DKK 65,591. The solvency ratio was 1.5%. The company had 1 employee in the financial year.
- Gross Profit
- DKK -15,000
- Profit/Loss
- DKK -11,963
- Equity
- DKK 65,591
- Total Assets
- DKK 4,281,071
- Employees
- 1
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2019
As of June 24, 2019, Hanne Damgaard Jensen has left the board of directors of ROS Therapeutics Holding ApS.
As of June 24, 2019, Mads Hartvig Clausen has left the board of directors of ROS Therapeutics Holding ApS.
As of June 24, 2019, Jon Bondebjerg has left the board of directors of ROS Therapeutics Holding ApS.
ROS Therapeutics Holding ApS has published its interim report for the period April 23, 2018 to December 31, 2018.
About ROS Therapeutics Holding ApS
ROS Therapeutics Holding ApS is a Danish company of the type Anpartsselskab based in København N, founded in 2018. The company is registered under the industry Ikke-finansielle holdingselskaber. The management consists of Hanne Damgaard Jensen. The company is owned by SPORCON LIFESCIENCE ADVISORS ApS and HDJ & LEJ Invest ApS. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -10,750 and a net result of DKK -26,512 compared with DKK -14,342 the year before. Equity in the 2025 report amounted to DKK -116,804.
